17th October 2024
At Festival of Biologics 2024 in San Diego, Krishgen Biosystems Pvt Ltd unveiled a poster showcasing its novel ELISA method for pharmacokinetic assessment (PKA) of the antibody-drug conjugate Sacituzumab Govitecan.
(inner blurb) The study demonstrated a robust, high-sensitivity assay for quantifying Sacituzumab Govitecan in preclinical and clinical samples, ensuring reproducibility and minimal matrix interference. Designed to support bioanalytical workflows, this ELISA enables reliable monitoring of ADC exposure and performance, underscoring Krishgen’s expertise in developing validated immunoassays for complex biologics.